

This is being deposited with the United States Patent Office via the
"Electronic Filing System" service under 37 CFR 1.10 on the date indicated
below and is addressed to

PATENT
Attorney Docket No.: 061877-5001-US
Client Ref. No.: P1081US10

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On April 14, 2006

MORGAN, LEWIS and BOCKIUS LLP

By: /Kathryn A. Degliantoni/

Kathryn A. Degliantoni

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

He, Yun *et al.*

Application No.: 10/690,802

Filed: October 21, 2003

For: OXINDOLES WITH ANTI-HIV
ACTIVITY

Customer No.: 47930

Confirmation Number: 9439

Examiner: Saeed, Kamal

Technology Center/Art Unit: 1626

RESPONSE TO RESTRICTION
REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated March 24, 2006, please enter
the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this
paper.


Remarks/Arguments begin on page 7 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1 1. (Previously presented) A compound having the formula:



2
3 wherein

4 R¹, R², R³ and R⁴ are members independently selected from H, substituted or
5 unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or
6 unsubstituted aryl, substituted or unsubstituted heteroaryl, OR⁸, NO₂, CN
7 and halogen

8 wherein

9 R⁸ is a member selected from H and substituted or unsubstituted alkyl;
10 R⁵ and R^{5'} are members independently selected from H, substituted or
11 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or
12 unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or
13 unsubstituted heteroaryl, CN, SR⁹ and C(O)R⁹

14 wherein

15 R⁹ is a member selected from H, substituted or unsubstituted alkyl,
16 substituted or unsubstituted heteroalkyl, substituted or
17 unsubstituted aryl, NR¹⁰R¹¹ and OR¹¹

18 wherein

19 R¹⁰ is a member selected from H, substituted or unsubstituted alkyl
20 and OR¹²

21 wherein

22 R^{12} is a member selected from H, substituted or
23 unsubstituted alkyl and substituted or unsubstituted
24 heteroalkyl;

25 R^{11} is a member selected from H, $C(O)R^{13}$, substituted or
26 unsubstituted alkyl, substituted or unsubstituted
27 heteroalkyl, substituted or unsubstituted aryl and
28 substituted or unsubstituted heterocycloalkyl, and wherein
29 R^{10} and R^{11} , together with the nitrogen to which they are
30 bound, are optionally joined to form a substituted or
31 unsubstituted heterocycloalkyl ring system having from 3
32 to 7 members

33 wherein

34 R^{13} is a member selected from H, substituted or
35 unsubstituted alkyl, substituted or unsubstituted
36 heteroalkyl and $NR^{14}R^{15}$

37 wherein

38 R^{14} and R^{15} are members independently selected
39 from H, substituted or unsubstituted alkyl
40 and substituted or unsubstituted heteroalkyl;

41 R^6 and R^6 are members independently selected from H, substituted or
42 unsubstituted alkyl and $C(O)R^{16}$;

43 wherein

44 R^{16} is a member selected from substituted or unsubstituted alkyl,
45 substituted or unsubstituted heteroalkyl, $NR^{17}R^{18}$ and OR^{17}

46 wherein

47 R^{17} and R^{18} are members independently selected from H,
48 substituted or unsubstituted alkyl, substituted or

49 unsubstituted heteroalkyl and substituted or unsubstituted
50 aryl; and


51 R^7 is a member selected from H, substituted or unsubstituted alkyl and substituted
52 or unsubstituted heteroalkyl.

1 **2.** (Previously presented) The compound according to claim **1**, wherein at
2 least one of R^5 and $R^{5'}$ is a member selected from substituted or unsubstituted phenyl, substituted
3 or unsubstituted pyridyl, substituted or unsubstituted furanyl, substituted or unsubstituted
4 benzofuranyl, substituted or unsubstituted quinolinyl, and substituted or unsubstituted thienyl.


1 **3.** (Previously presented) The compound according to claim **1**, wherein at
2 least one of R^{10} and R^{11} is substituted or unsubstituted C_1 - C_6 alkyl.

1 **4.** (Previously presented) The compound according to claim **1**, wherein at
2 least one of R^6 and $R^{6'}$ is a member selected from substituted or unsubstituted C_1 - C_6 alkyl.

1 **5.** (Previously presented) The compound according to claim **1**, having the
2 formula:




6. (Previously presented) The compound according to claim 5, having the formula:



7. (Previously presented) The compound according to claim 6, wherein R¹¹ is substituted or unsubstituted C₁-C₄ alkyl.

8. (Previously presented) The compound according to claim 5, wherein at least one of R⁵ and R^{5'} is a member selected from substituted and unsubstituted:



9. (Previously presented) The compound according to claim 5, wherein R⁶ and R^{6'} are independently selected from substituted or unsubstituted methyl and substituted or unsubstituted ethyl.

10. (Previously presented) A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. (Previously presented) A method of inhibiting HIV in a cell, said method comprising contacting said cell with an amount of a compound according to claim 1 sufficient to inhibit said HIV.

1 **12.** (Previously presented) A method of inhibiting reverse transcriptase in a
2 cell, said method comprising contacting said cell with an amount of a compound according to
3 claim **1** sufficient to inhibit said reverse transcriptase.

1 **13.** (Previously presented) The method according to claim **11**, wherein said
2 cell is in a human.

1 **14.** (Previously presented) The method according to claim **12**, wherein said
2 cell is in a human.

1 **15.** (Previously presented) A method of treating HIV infection in a human
2 subject comprising administering to said subject an amount of a compound according to claim **1**,
3 sufficient to treat said HIV infection.

1 **16.** (Previously presented) A method of providing prophylaxis against HIV
2 infection comprising administering a prophylactic amount of a compound according to claim **1** to
3 a person who is at risk of HIV infection.

1 **17.** (Previously presented) The method according to claim **15**, wherein said
2 HIV is a drug resistant mutant.